Patients with supraventricular tachycardia presenting with aborted sudden death: incidence, mechanism and long-term follow-up

Department of Medicine, University of California, San Francisco.

A total of 13 (4.5%) of 290 patients with aborted sudden death had either documented (7; 54%) or strong presumptive evidence of supraventricular tachycardia that deteriorated into ventricular fibrillation. Six (46%) of the 13 had an accessory conduction pathway and either atrial fibrillation (5 patients) or paroxysmal atrioventricular (AV) reentrant tachycardia (1 patient) that deteriorated into ventricular fibrillation. Three patients with AV node reentrant tachycardia and four with atrial fibrillation and enhanced AV node conduction presented with supraventricular arrhythmias that deteriorated into ventricular fibrillation. Patients were treated with medical, surgical or catheter ablative procedures designed to prevent recurrences of supraventricular arrhythmias. Four patients received an implanted automatic defibrillator, but none had an appropriate device discharge. Over a follow-up period of 41.6 +/- 33.6 months, 12 patients are alive without symptomatic arrhythmias. One patient died because of severe chronic lung disease and heart failure. Supraventricular tachycardia was the cause of aborted sudden death in approximately 5% of patients referred for evaluation of sudden cardiac death. Treatment directed at prevention of supraventricular tachycardia was associated with an excellent prognosis. Current treatment techniques appear to obviate the need for automatic defibrillator therapy in these patients.

This article has been cited by other articles:

				Writing Group Members, V. L. Roger, A. S. Go, D. M. Lloyd-Jones, E. J. Benjamin, J. D. Berry, W. B. Borden, D. M. Bravata, S. Dai, E. S. Ford, et al. Heart Disease and Stroke Statistics--2012 Update: A Report From the American Heart Association Circulation, January 3, 2012; 125(1): e2 - e220. [Full Text] [PDF]

				D. Bansch, H. Kottkamp, G. Gronefeld, J. Vogt, C. Israel, D. Bocker, G. Hindricks, K.-H. Kuck, and on behalf of the Quick-ICD investigators The quick-implantable-defibrillator trial Europace, December 1, 2007; 9(12): 1144 - 1150. [Abstract] [Full Text] [PDF]

				M. M. Kreuzberg, J. W. Schrickel, A. Ghanem, J.-S. Kim, J. Degen, U. Janssen-Bienhold, T. Lewalter, K. Tiemann, and K. Willecke Connexin30.2 containing gap junction channels decelerate impulse propagation through the atrioventricular node PNAS, April 11, 2006; 103(15): 5959 - 5964. [Abstract] [Full Text] [PDF]

				P Mazeika Aborted sudden cardiac death: a clinical perspective Postgrad. Med. J., June 1, 2001; 77(908): 363 - 370. [Abstract] [Full Text]

				T. J. Lessmeier, D. Gamperling, V. Johnson-Liddon, B. S. Fromm, R. T. Steinman, M. D. Meissner, and M. H. Lehmann Unrecognized Paroxysmal Supraventricular Tachycardia: Potential for Misdiagnosis as Panic Disorder Arch Intern Med, March 10, 1997; 157(5): 537 - 543. [Abstract] [PDF]

				A. E. Epstein, W. M. Miles, D. G. Benditt, A. J. Camm, E. J. Darling, P. L. Friedman, A. Garson, J. C. Harvey, G. A. Kidwell, G. J. Klein, et al. Personal and Public Safety Issues Related to Arrhythmias That May Affect Consciousness: Implications for Regulation and Physician Recommendations: A Medical/Scientific Statement From the American Heart Association and the North American Society of Pacing and Electrophysiology Circulation, September 1, 1996; 94(5): 1147 - 1166. [Full Text]

				J. A. Reiffel Data-driven Decisions: The Importance of Clinical Trials in Arrhythmia Management Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1996; 1(1): 79 - 88. [Abstract] [PDF]

				R. H. Falk Proarrhythmia in Patients Treated for Atrial Fibrillation or Flutter Ann Intern Med, July 15, 1992; 117(2): 141 - 150. [Abstract] [PDF]